Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624065 · ClinicalTrials.gov registry record · Phase 3
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT00624065 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 348 participants.
The verdict
NCT00624065, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (\<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (\<140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.
Interventions
- DRUG carvedilol controlled release/lisinopril
- DRUG lisinopril + placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624065
The ClinicalTrials.gov registry entry for NCT00624065 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carvedilol controlled release/lisinopril is the first listed.
NCT00624065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624065 about?
NCT00624065 is a clinical study titled "Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure". Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (\<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitra...
What is the current status of trial NCT00624065?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2008-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00624065?
The interventions under investigation include: carvedilol controlled release/lisinopril (DRUG), lisinopril + placebo (DRUG).
Who is sponsoring clinical trial NCT00624065?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.